2 reports

  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • ASSET PURCHASE

The drug candidate was also under development for the treatment of cutaneous T-cell lymphoma, mantle cell lymphoma, colorectal cancer, lung cancer, non-small cell lung cancer, small-cell lung cancer, prostate cancer, metastatic breast cancer, gli

  • Biopharmaceutical
  • Cancer
  • United States
  • Deals & Alliance
  • Denovo Biopharma, LLC